Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03239340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03239340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 30, 2018
Completion date
September 19, 2023
Enrollment
154 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutation positive locally advanced or metastatic non-small cell lung cancer